A neurologist orders the wrong genetic test for a patient experiencing peripheral neuropathy and doesn't realize it even upon ...

The firm plans to put the proceeds toward further developing its cell therapy in CD33- or FLT3-expressing AML and for other R&D activities.

The agency is also evaluating if there's a need for further regulatory action based on reports of hematologic malignancies from clinical trials of the therapy.

The global Phase III VANCE trial of the autologous EBV-targeted T-cell therapy was the largest trial of a solid tumor cell ...

The Missouri hospital system designed its own 13-gene PGx panel, which it runs at its molecular genetics lab and calls the ...

As the popularity of drugs like Ozempic and Mounjaro soar, researchers, doctors, biotechs, and diagnostic firms see a role ...

The firms will initially develop a tool to identify NSCLC patients with EGFR mutations who can benefit from targeted therapy.

In a first-of-its-kind trial, physicians will review neurofilament test results with patients and decide whether to continue ...

Researchers worked with two labs to identify 16 consensus lower-risk pathogenic variants and are pushing for greater ...

The addition of tiragolumab to Tecentriq in patients with advanced PD-L1-high NSCLC failed to improve overall survival in a Phase III trial.

The EC considered the treatment's activity in patients with advanced, PD-L1-positive esophageal and gastric cancers in the RATIONALE-305 and -306 trials.

Sarepta will pay Arrowhead Pharmaceuticals $500 million upfront, make a $325 million equity investment, plus pay $250 million over five years, and more.